Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03551795
Recruitment Status : Recruiting
First Posted : June 11, 2018
Last Update Posted : June 11, 2018
Sponsor:
Information provided by (Responsible Party):
Xiaoyan Zhang, Shanghai Public Health Clinical Center

Brief Summary:
Invariant Natural killer T (iNKT) cells are a unique subset of lymphocytes that express homogeneous TCR recognizing KRN7000 which was up-regulated by many kinds of cancer cells.The hypothesis of the investigators is that immunotherapy strategy of infusion of iNKT cells may resist inflection and decrease the tumor burden and improve overall survival. The purpose of this study is to assess the safety and efficacy of treatment of tuberculosis with malignant solid tumor by infusing of iNKT cells.

Condition or disease Intervention/treatment Phase
Malignant Solid Tumor Biological: Infusion of iNKT cells Phase 1 Phase 2

Detailed Description:

Treatment of tuberculosis with malignant solid tumor is great unsolved challenge to the physicians. Efficacy of conventional treatment, such as surgery, radiotherapy and chemotherapy is limited. AS novel therapy, immunotherapy shows great prospects.

Human iNKT cells can directly lysis tumor cells by a perforin-dependent mechanism,and intracellular granzyme B expression may also potentiate cell killing. Tumor cells expressing CD1d may be especially susceptible to direct NKT cell lysis. iNKT cells play important role in immune regulation by secreting various cytokines. Expansion method of iNKT cells in vitro is developed as published in the patent of the investigators. Infusion of iNKT cells has been proved safe in mice.

In this clinical trial, the safety and efficacy of the immunotherapy of infusion of iNKT cells are assessed.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor
Actual Study Start Date : January 1, 2018
Estimated Primary Completion Date : June 30, 2019
Estimated Study Completion Date : December 31, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tuberculosis

Arm Intervention/treatment
Experimental: treatment
The eligible patient receive the experimental infusion of iNKT cells.
Biological: Infusion of iNKT cells
The eligible patients receive twice infusions of iNKT cells(1E8~1E10) in one course of treatment.




Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: up to 4 months post-infection ]
    Change of target focus confirmed by CT or MRI


Secondary Outcome Measures :
  1. Incidence of adverse events related to the infusion of cells [ Time Frame: 28 days post-infusion ]
    The incidence of adverse events following infusion of iNKT cells


Other Outcome Measures:
  1. Progression-Free Survival (PFS) [ Time Frame: Approximately 1 years after the treatment ]
    Progression-Free Survival (PFS)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological or cytologically diagnosis of tuberculosis with malignant solid tumor
  • Patients' tumor tissue (formalin-fixed, paraffin-embedded) must be sufficient for diagnosis of cancer by a certified Laboratory of Pathology
  • Laboratory values within the following ranges prior to receiving treatment of study agent: Hemoglobin≧8.0 g/dL, Neutrophils count≧1E9/L, Lymphocytes count≧lower limit of institutional normal, Platelet count≧50E9/L, Serum creatinine≦2.0 mg/dL, Serum bilirubin≦2 x upper limit of institutional normal, AST/ALT≦2 x upper limit of institutional normal
  • No dyspnea at rest. Oxygen saturation ≥90% on room air
  • No genetic disease
  • Fertile females/males must consent to use contraceptives during participation of the trial. Women of child bearing potential must have a negative pregnancy test prior to receiving treatment of study agent within 7 days
  • Patients must have a Karnofsky performance status greater than or equal to 80%
  • Able and willing to give witnessed, written informed consent form prior to receiving any study related procedure
  • Agrees to participate in long-term follow-up for up to 1 years, if received NKT infusion

Exclusion Criteria:

  • Organ dysfunction,such as significant cardiovascular disease, myocardial infarction within the past six months, unstable angina, coronary angioplasty within the past six months, uncontrolled atrial or ventricular cardiac arrhythmias; Child-Pugh C; Renal function failure or uremia; Respiratory failure; Disturbance of consciousness; Renal failure.
  • Suffering from lymphoma or leukemia
  • Serious infections requiring antibiotics, bleeding disorders
  • Patients with myelodysplastic syndrome (MDS)
  • History of immunodeficiency disease or autoimmune disease
  • Positive HIV antigen and antibody, Hepatitis B surface antigen and Hepatitis C PCR within 21 days prior to enrollment
  • Within concurrent chemotherapy
  • Concurrent other medical condition that would prevent the patient from undergoing protocol-based therapy
  • Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agent
  • Pregnant or breast-feeding patients
  • Can't give informed consent
  • Lack of availability for follow-up assessment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03551795


Contacts
Layout table for location contacts
Contact: Yan X Zhang, Ph.D 0086-021-37990333 ext 7310 zhangxiaoyan@shaphc.org
Contact: Qing J Xu, Ph.D

Locations
Layout table for location information
China
Shanghai Public Health Clinical Center, Fudan University Recruiting
Shanghai, China, 201508
Contact: Yan X Zhang, Ph.D         
Sponsors and Collaborators
Xiaoyan Zhang
Investigators
Layout table for investigator information
Study Chair: Qing J Xu, Ph.D Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Jin Shan, Shanghai 201508, P.R. China

Layout table for additonal information
Responsible Party: Xiaoyan Zhang, Principal Investigator, Shanghai Public Health Clinical Center
ClinicalTrials.gov Identifier: NCT03551795     History of Changes
Other Study ID Numbers: iNKT20180427V1.1
First Posted: June 11, 2018    Key Record Dates
Last Update Posted: June 11, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Tuberculosis
Neoplasms
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections